マーケットレポート詳細

リキッドバイオプシー(液体生検)の世界市場:循環バイオマーカー別、用途別2027年予測

Liquid Biopsy Market by Product (Assay Kits, Instruments), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast), Non-Cancer), Sample Type (Blood), End User (Reference Lab, Hospitals) - Global Forecast to 2027

出版元:MarketsandMarkets   出版元について
発行年:2022年11月
定価 :Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文263ページになります。
商品コード:MAM3110

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

リキッドバイオプシー(液体生検) の世界市場規模は2022年で43億ドル、2027年に100億ドルになると見込まれます。また、市場の平均年成長率は18.3%に達すると予測されています。
レポートはリキッドバイオプシーの世界市場について2027年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測(循環バイオマーカー別市場、技術別市場、等)を中心に構成されています。また競合状況、主要企業情報(11社)、市場ダイナミクス、価格分析などの分析も加味し、リキッドバイオプシー市場の動向および今後成長性を詳細にレポートしています。

【レポート構成概要】

◆リキッドバイオプシー(液体生検)の世界市場予測2020-2027年

・市場規模(US$)

◆製品、サービス別、市場-2027年

・分析キット
・機器
・サービス
※(市場規模US$)

◆循環バイオマーカー別、市場-2027年

・循環腫瘍細胞(CTC)
・循環腫瘍DNA
・セルフリーDNA (CFDNA)
・細胞外小胞(EVS)
・その他循環バイオマーカー
※(市場規模US$)

◆技術別、市場-2027年

・NGSを用いたマルチゲノム解析
・マイクロアレイを用いたシングルゲノム解析
※(市場規模US$)

◆用途別、市場-2027年

がん
・肺がん
・乳がん
・結腸直腸がん
・前立腺がん
・メラノーマ
・その他がん

がん以外
・非侵襲性出生前診断(NIPT)
・臓器移植検査
・感染症検査
※(市場規模US$)

◆臨床用途別、市場-2027年

・治療選択
・治療モニタリング
・再発モニタリング
・早期がんスクリーニング検査
※(市場規模US$)

◆サンプル別、市場-2027年

・血液
・その他サンプル
※(市場規模US$)

◆エンドユーザー別、市場-2027年

・リファレンスラボラトリー
・病院、医院
・学術機関 、研究施設
・その他エンドユーザー
※(市場規模US$)

◆主要国地域別市場-2027年

北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
中南米
中東アフリカ
※地域別に全セグメントの細分化データ掲載、詳細は目次参照
※国別に各種 セグメント別(用途別小分類以外)の細分化 データ掲載

◆市場分析

・市場ダイナミクス(促進要因、障壁、機会、課題)
・価格分析
・特許分析
・バリューチェーン分析
・サプライチェーン分析
・エコシステム
・業界構造分析(ファイブフォース分析)
・規制動向
・貿易分析
・キーステークホルダー、購買基準
・市場シェア分析
・競合状況

◆液体生検の主要企業プロフィール動向

・QIAGEN NV
・F HOFFMANN-LA ROCHE AG
・MYRIAD GENETICS, INC
・THERMO FISHER SCIENTIFIC, INC
・GUARDANT HEALTH, INC
・BIO-RAD LABORATORIES, INC
・ILLUMINA, INC
・EXACT SCIENCES CORPORATION
・SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
・BIOCEPT, INC
・MDXHEALTH

その他プレイヤー
・NEOGENOMICS, INC
・EPIGENOMICS AG
・ANGLE PLC
・MENARINI-SILICON BIOSYSTEMS
・VORTEX BIOSCIENCES, INC
・EXOSOME DIAGNOSTICS, INC
・MEDGENOME INC
・AGENA BIOSCIENCE, INC
・PERSONAL GENOME DIAGNOSTICS, INC
・FREENOME HOLDINGS, INC
・STRAND LIFE SCIENCES
・LUNGLIFE AI, INC
・LUCENCE HEALTH INC
・ANPAC BIO-MEDICAL SCIENCE CO, LTD
(全263 頁)


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次)

1      INTRODUCTION

1.1             STUDY OBJECTIVES
1.2             MARKET DEFINITION
1.2.1              INCLUSIONS & EXCLUSIONS
1.3             STUDY SCOPE
1.3.1              LIQUID BIOPSY MARKET
1.3.2              REGIONAL SCOPE
1.3.3              YEARS CONSIDERED   37
1.4             CURRENCY
1.5             LIMITATIONS
1.6             STAKEHOLDERS
1.7             SUMMARY OF CHANGES

2      RESEARCH METHODOLOGY

2.1             RESEARCH DATA
2.2             RESEARCH APPROACH
FIGURE 1       LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1              SECONDARY DATA
2.2.1.1            KEY DATA FROM SECONDARY SOURCES
2.2.2              PRIMARY DATA
2.2.2.1            PRIMARY SOURCES
2.2.2.2            KEY DATA FROM PRIMARY SOURCES
2.2.2.3            KEY INDUSTRY INSIGHTS
2.2.2.4            BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 2       BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3       BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3             MARKET SIZE ESTIMATION
2.3.1              BOTTOM-UP APPROACH
2.3.1.1            APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 4       BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2            APPROACH 2: PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS
2.3.1.3            CAGR PROJECTIONS
FIGURE 5       CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2              TOP-DOWN APPROACH   48
FIGURE 6       LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
2.4             MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7       DATA TRIANGULATION METHODOLOGY
2.5             MARKET SHARE
2.6             STUDY ASSUMPTIONS
2.7             GROWTH RATE ASSUMPTIONS
2.8             RISK ASSESSMENT
2.8.1              RISK ASSESSMENT: LIQUID BIOPSY MARKET

3      EXECUTIVE SUMMARY

FIGURE 8       LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 9       LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022 VS. 2027 (USD MILLION)
FIGURE 10     LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 11     LIQUID BIOPSY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12     LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 13     LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 14     LIQUID BIOPSY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 15     LIQUID BIOPSY MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4      PREMIUM INSIGHTS

4.1             LIQUID BIOPSY MARKET OVERVIEW
FIGURE 16     RISING INCIDENCE OF CANCER TO DRIVE GROWTH IN LIQUID BIOPSY MARKET
4.2             LIQUID BIOPSY MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027
FIGURE 17     ASSAY KITS TO CONTINUE TO DOMINATE LIQUID BIOPSY MARKET DURING FORECAST PERIOD
4.3             LIQUID BIOPSY MARKET SHARE, BY CIRCULATING BIOMARKER, 2022 VS. 2027
FIGURE 18     CIRCULATING TUMOR CELLS TO CONTINUE TO DOMINATE MARKET IN 2027
4.4             LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2022 VS. 2027
FIGURE 19     THERAPY SELECTION SEGMENT TO HOLD LARGEST SHARE OF MARKET DURING FORECAST PERIOD

4.5             LIQUID BIOPSY MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
FIGURE 20     MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO HOLD LARGER SHARE OF MARKET IN 2027
4.6             LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2022 VS. 2027
FIGURE 21     CANCER APPLICATIONS TO LEAD MARKET IN 2027
4.7             LIQUID BIOPSY MARKET SHARE, BY SAMPLE TYPE, 2022 VS. 2027
FIGURE 22     BLOOD TYPE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027
4.8             LIQUID BIOPSY MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 23     REFERENCE LABORATORIES TO DRIVE MARKET GROWTH IN 2027
4.9             LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 24     ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN LIQUID BIOPSY MARKET DURING FORECAST PERIOD

5      MARKET OVERVIEW

5.1             INTRODUCTION
5.2             MARKET DYNAMICS
FIGURE 25     LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1              DRIVERS
5.2.1.1            RISING INCIDENCE AND PREVALENCE OF CANCER
TABLE 1         NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
5.2.1.2            CANCER AWARENESS INITIATIVES UNDERTAKEN BY GLOBAL HEALTH ORGANIZATIONS
5.2.1.3            INCREASING PREFERENCE FOR NON-INVASIVE TREATMENT PROCEDURES
5.2.2              RESTRAINTS
5.2.2.1            LOWER SENSITIVITY OF CERTAIN LIQUID BIOPSY PROCEDURES
5.2.3              OPPORTUNITIES
5.2.3.1            GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS
5.2.3.2            GROWTH OPPORTUNITIES IN EMERGING COUNTRIES
5.2.4              CHALLENGES
5.2.4.1            UNCLEAR REIMBURSEMENT SCENARIO
5.3             PRICING ANALYSIS
TABLE 2         AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT
TABLE 3         AVERAGE SELLING PRICE TREND   69
5.4             PATENT ANALYSIS
FIGURE 26     PATENT ANALYSIS OF LIQUID BIOPSY
TABLE 4         PATENT ANALYSIS
5.5             VALUE CHAIN ANALYSIS
FIGURE 27     MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASE
5.6             SUPPLY CHAIN ANALYSIS
FIGURE 28     LIQUID BIOPSY MARKET: SUPPLY CHAIN ANALYSIS
5.7             ECOSYSTEM ANALYSIS OF LIQUID BIOPSY MARKET
FIGURE 29     LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS
5.7.1              LIQUID BIOPSY MARKET: ROLE IN ECOSYSTEM
5.8             PORTER’S FIVE FORCES ANALYSIS
TABLE 5         LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1              THREAT FROM NEW ENTRANTS
5.8.2              THREAT FROM SUBSTITUTES
5.8.3              BARGAINING POWER OF BUYERS
5.8.4              BARGAINING POWER OF SUPPLIERS
5.8.5              DEGREE OF COMPETITION
5.9             REGULATORY LANDSCAPE
5.9.1              REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6         NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7         EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8         ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9         LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10       REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.2              NORTH AMERICA
5.9.2.1            US
5.9.2.2            CANADA
5.9.3              EUROPE
5.9.4              ASIA PACIFIC
5.9.4.1            CHINA
5.9.4.2            JAPAN
5.9.5              LATIN AMERICA
5.9.5.1            BRAZIL
5.9.5.2            MEXICO
5.9.6              MIDDLE EAST
5.9.7              AFRICA
5.10          TECHNOLOGY ANALYSIS
5.11          PESTLE ANALYSIS
5.12          TRADE ANALYSIS
5.12.1            TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.12.1.1          EXPORT SCENARIO FOR LIQUID BIOPSY

 

TABLE 11       EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
5.12.1.2          IMPORT SCENARIO FOR LIQUID BIOPSY
TABLE 12       IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 13       IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (TONS)
5.13          KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 14       LIQUID BIOPSY MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.14          TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.14.1            REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS
FIGURE 30     REVENUE SHIFT FOR LIQUID BIOPSY MARKET
5.15          KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1            KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 31     INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS & SERVICES
TABLE 15       INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS & SERVICES
5.15.2            BUYING CRITERIA   88
FIGURE 32     KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS & SERVICES
TABLE 16       KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS & SERVICES
5.16          CASE STUDY ANALYSIS
5.16.1            CASE STUDY 1
5.16.2            CASE STUDY 2

6      LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE

6.1             INTRODUCTION
TABLE 17       LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
6.2             ASSAY KITS
6.2.1              RECURRENT REQUIREMENT AND PURCHASES OF ASSAY KITS TO DRIVE GROWTH
TABLE 18       KEY PRODUCTS IN ASSAY KITS MARKET
TABLE 19       LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3             INSTRUMENTS
6.3.1              LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH
TABLE 20       KEY PRODUCTS IN INSTRUMENTS MARKET
TABLE 21       LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4             SERVICES
6.4.1              INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT MARKET GROWTH
TABLE 22       LIQUID BIOPSY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)

7      LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

7.1             INTRODUCTION
TABLE 23       LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
7.2             CIRCULATING TUMOR CELLS (CTC)
7.2.1              EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF OVERALL TUMOR BURDEN TO DRIVE DEMAND
TABLE 24       LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2020–2027 (USD MILLION)
7.3             CIRCULATING TUMOR DNA (CTDNA)
7.3.1              ABILITY OF CTDNA ANALYSIS TO SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS TO DRIVE MARKET
TABLE 25       LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2020–2027 (USD MILLION)
7.4             CELL-FREE DNA (CFDNA)
7.4.1              GROWING APPLICATION OF CFDNA IN PRENATAL SCREENING TO DRIVE GROWTH
TABLE 26       LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2020–2027 (USD MILLION)
7.5             EXTRACELLULAR VESICLES (EVS)
7.5.1              ABILITY TO REMAIN STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES TO ENSURE CONSISTENT GROWTH IN MARKET
TABLE 27       LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2020–2027 (USD MILLION)
7.6             OTHER CIRCULATING BIOMARKERS
TABLE 28       LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2020–2027 (USD MILLION)

8      LIQUID BIOPSY MARKET, BY TECHNOLOGY

8.1             INTRODUCTION
TABLE 29       LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.2             MULTI-GENE PARALLEL ANALYSIS USING NGS
8.2.1              HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO DRIVE GROWTH
TABLE 30       LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2020–2027 (USD MILLION)  104
8.3             SINGLE-GENE ANALYSIS USING PCR MICROARRAYS

8.3.1              COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
TABLE 31       LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2020–2027 (USD MILLION)

9      LIQUID BIOPSY MARKET, BY APPLICATION

9.1             INTRODUCTION
TABLE 32       LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2             CANCER APPLICATIONS
TABLE 33       GLOBAL CANCER INCIDENCE, 2020 VS. 2040 (MILLION)
TABLE 34       LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 35       LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
9.2.1              LUNG CANCER
9.2.1.1            GROWING PREVALENCE OF LUNG CANCER TO PROPEL MARKET GROWTH
TABLE 36       GLOBAL LUNG CANCER INCIDENCE, 2020 VS. 2040
TABLE 37       LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION)
9.2.2              BREAST CANCER
9.2.2.1            INCREASING GOVERNMENT FUNDING FOR BREAST CANCER RESEARCH TO SPUR GROWTH
TABLE 38       GLOBAL BREAST CANCER INCIDENCE, 2020 VS. 2040
TABLE 39       LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION)
9.2.3              COLORECTAL CANCER   112
9.2.3.1            RISING PREVALENCE OF COLORECTAL CANCER TO PROPEL MARKET
TABLE 40       GLOBAL COLORECTAL CANCER INCIDENCE, 2020 VS. 2040
TABLE 41       LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION)
9.2.4              PROSTATE CANCER   114
9.2.4.1            GROWING NUMBER OF PROSTATE CANCER PATIENTS TO SUPPORT MARKET GROWTH
TABLE 42       GLOBAL PROSTATE CANCER INCIDENCE, 2020 VS. 2040
TABLE 43       LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION)
9.2.5              MELANOMA
9.2.5.1            GROWING NEED FOR EARLY DIAGNOSIS OF GENETICALLY MUTATED TUMORS TO DRIVE MARKET GROWTH
TABLE 44       GLOBAL MELANOMA INCIDENCE, 2020 VS. 2040
TABLE 45       LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2020–2027 (USD MILLION)
9.2.6              OTHER CANCERS
TABLE 46       GLOBAL INCIDENCE OF OTHER CANCERS, 2020
TABLE 47       LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION)
9.3             NON-CANCER APPLICATIONS
TABLE 48       LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 49       LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
9.3.1              NON-INVASIVE PRENATAL TESTING (NIPT)
9.3.1.1            GROWING DEMAND FOR NIPT IN HIGH-RISK PREGNANCIES TO DRIVE GROWTH   119
TABLE 50       LIQUID BIOPSY MARKET FOR NIPT, BY REGION, 2020–2027 (USD MILLION)
9.3.2              ORGAN TRANSPLANTATIONS
9.3.2.1            NEED FOR EARLY DETECTION OF REJECTION TO IMPROVE SURVIVAL CHANCES TO DRIVE GROWTH
TABLE 51       LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATIONS, BY REGION, 2020–2027 (USD MILLION)
9.3.3              INFECTIOUS DISEASE TESTING
9.3.3.1            POTENTIAL TO RELIABLY IDENTIFY A WIDE VARIETY OF INFECTIONS TO DRIVE ADOPTION
TABLE 52       LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2020–2027 (USD MILLION)

10   LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION

10.1          INTRODUCTION
TABLE 53       LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
10.2          THERAPY SELECTION
10.2.1            GROWING PREFERENCE DUE TO NON-INVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE GROWTH   123
TABLE 54       LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2020–2027 (USD MILLION)
10.3          TREATMENT MONITORING
10.3.1            ABILITY TO QUANTITATIVELY CALCULATE CONCENTRATIONS OF CANCER-RELATED MUTATIONS TO FUEL DEMAND
TABLE 55       LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2020–2027 (USD MILLION)
10.4          RECURRENCE MONITORING
10.4.1            ABILITY TO DETECT CANCER MUTATIONS THROUGH CTDNA TO DRIVE GROWTH
TABLE 56       LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2020–2027 (USD MILLION)

10.5          EARLY CANCER SCREENING
10.5.1            POTENTIAL OF LIQUID BIOPSY TO DETECT CANCER IN EARLY STAGES TO DRIVE MARKET
TABLE 57       LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2020–2027 (USD MILLION)

11   LIQUID BIOPSY MARKET, BY SAMPLE TYPE

11.1          INTRODUCTION
TABLE 58       LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 59       LIQUID BIOPSY SAMPLES AND APPLICATIONS
11.2          BLOOD
11.2.1            SIMPLE AND NON-INVASIVE NATURE TO DRIVE MARKET GROWTH
TABLE 60       LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY REGION, 2020–2027 (USD MILLION)
11.3          OTHER SAMPLE TYPES
TABLE 61       LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2020–2027 (USD MILLION)

12   LIQUID BIOPSY MARKET, BY END USER

12.1          INTRODUCTION
TABLE 62       LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
12.2          REFERENCE LABORATORIES
12.2.1            INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES TO DRIVE GROWTH
TABLE 63       LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
12.3          HOSPITALS AND PHYSICIAN LABORATORIES
12.3.1            GROWING NUMBER OF HOSPITALS WORLDWIDE TO BOOST GROWTH
TABLE 64       LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
12.4          ACADEMIC & RESEARCH CENTERS
12.4.1            GROWING FOCUS OF RESEARCH FOR DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO FUEL GROWTH
TABLE 65       LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2020–2027 (USD MILLION)
12.5          OTHER END USERS
TABLE 66       LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)

13   LIQUID BIOPSY MARKET, BY REGION

13.1          INTRODUCTION
TABLE 67       LIQUID BIOPSY MARKET, BY REGION, 2020–2027 (USD MILLION)
13.2          NORTH AMERICA
TABLE 68       NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY TYPE OF CANCER, 2020
FIGURE 33     NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
TABLE 69       NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70       NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 71       NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 72       NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 73       NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 74       NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 75       NORTH AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 76       NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.2.1            US
13.2.1.1          INCREASING PREVALENCE OF CANCER TO DRIVE GROWTH
TABLE 77       US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 78       US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 79       US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 80       US: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 81       US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 82       US: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 83       US: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.2.2            CANADA
13.2.2.1          AVAILABILITY OF VARIOUS CANCER SCREENING PROGRAMS TO DRIVE GROWTH
TABLE 84       CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 85       CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)

TABLE 86       CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 87       CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 88       CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 89       CANADA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 90       CANADA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.3          EUROPE
TABLE 91       EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92       EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 93       EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 94       EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 95       EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 96       EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 97       EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 98       EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.3.1            GERMANY
13.3.1.1          FAVORABLE GOVERNMENT HEALTH POLICIES TO SUPPORT MARKET GROWTH
TABLE 99       GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 100     GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 101     GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 102     GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 103     GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 104     GERMANY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 105     GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.3.2            UK
13.3.2.1          INCREASING NUMBER OF DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH
TABLE 106     UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 107     UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 108     UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 109     UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 110     UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 111     UK: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 112     UK: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.3.3            FRANCE
13.3.3.1          RISING R&D EXPENDITURE TO DRIVE MARKET GROWTH
TABLE 113     FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 114     FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 115     FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 116     FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 117     FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 118     FRANCE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 119     FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.3.4            ITALY
13.3.4.1          GROWING RESEARCH ON DISCOVERY OF NOVEL CIRCULATING CANCER BIOMARKERS TO DRIVE MARKET GROWTH
TABLE 120     ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 121     ITALY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 122     ITALY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 123     ITALY: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 124     ITALY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 125     ITALY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 126     ITALY: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.3.5            SPAIN
13.3.5.1          GROWING FOCUS ON PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
TABLE 127     SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)

TABLE 128     SPAIN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 129     SPAIN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 130     SPAIN: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 131     SPAIN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 132     SPAIN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 133     SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.3.6            REST OF EUROPE
TABLE 134     REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 135     REST OF EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 136     REST OF EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 137     REST OF EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 138     REST OF EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 139     REST OF EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 140     REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.4          ASIA PACIFIC
FIGURE 34     ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT
TABLE 141     ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 142     ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 143     ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 144     ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 145     ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 146     ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 147     ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 148     ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.4.1            CHINA
13.4.1.1          GROWING PUBLIC ACCESS TO ADVANCED HEALTHCARE FACILITIES TO DRIVE MARKET  176
TABLE 149     CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 150     CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 151     CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 152     CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 153     CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 154     CHINA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 155     CHINA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.4.2            JAPAN
13.4.2.1          UNIVERSAL HEALTHCARE REIMBURSEMENT POLICY TO FUEL GROWTH
TABLE 156     JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 157     JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 158     JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 159     JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 160     JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 161     JAPAN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 162     JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.4.3            INDIA
13.4.3.1          INCREASING PRIVATE & PUBLIC INVESTMENTS IN HEALTHCARE SYSTEM TO BOOST MARKET
TABLE 163     INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 164     INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 165     INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 166     INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 167     INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 168     INDIA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 169     INDIA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.4.4            REST OF ASIA PACIFIC
TABLE 170     REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 171     REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 172     REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 173     REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 174     REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 175     REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 176     REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.5          LATIN AMERICA
13.5.1            INCREASING PRIVATE & PUBLIC INVESTMENTS TO DRIVE MARKET
TABLE 177     LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 178     LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 179     LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 180     LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 181     LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 182     LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 183     LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)
13.6          MIDDLE EAST & AFRICA
13.6.1            INCREASING FUNDING IN RESEARCH TO DRIVE MARKET GROWTH
TABLE 184     MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 185     MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION)
TABLE 186     MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 187     MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 188     MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION)
TABLE 189     MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION)
TABLE 190     MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION)

14   COMPETITIVE LANDSCAPE

14.1          OVERVIEW
14.2          STRATEGIES OF KEY PLAYERS
14.2.1            OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET
TABLE 191     OVERVIEW OF STRATEGIES DEPLOYED BY KEY LIQUID BIOPSY COMPANIES
14.3          REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 35     REVENUE SHARE ANALYSIS OF TOP PLAYERS IN LIQUID BIOPSY MARKET
14.4          MARKET SHARE ANALYSIS
14.4.1            LIQUID BIOPSY MARKET
FIGURE 36     LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2021)
TABLE 192     LIQUID BIOPSY MARKET SHARE: DEGREE OF COMPETITION
14.5          COMPANY EVALUATION QUADRANT
14.5.1            LIST OF EVALUATED VENDORS
14.5.2            STARS
14.5.3            EMERGING LEADERS
14.5.4            PERVASIVE PLAYERS
14.5.5            PARTICIPANTS
FIGURE 37     LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
14.6          COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
14.6.1            PROGRESSIVE COMPANIES
14.6.2            STARTING BLOCKS   202
14.6.3            RESPONSIVE COMPANIES
14.6.4            DYNAMIC COMPANIES   202
FIGURE 38     LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
14.7          COMPETITIVE BENCHMARKING
14.7.1            PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
FIGURE 39     PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN LIQUID BIOPSY MARKET
TABLE 193     LIQUID BIOPSY MARKET: COMPANY GEOGRAPHICAL FOOTPRINT
TABLE 194     LIQUID BIOPSY MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 195     LIQUID BIOPSY MARKET: DETAILED LIST OF KEY START-UPS/SMES
14.8          COMPETITIVE SCENARIO
14.8.1            PRODUCT LAUNCHES & APPROVALS
TABLE 196     KEY PRODUCT LAUNCHES & APPROVALS
14.8.2            DEALS
TABLE 197     KEY DEALS

15   COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
15.1          KEY PLAYERS
15.1.1            QIAGEN N.V.
TABLE 198     QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 40     QIAGEN N.V.: COMPANY SNAPSHOT (2021)
15.1.2            F. HOFFMANN-LA ROCHE AG
TABLE 199     F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
FIGURE 41     F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
15.1.3            MYRIAD GENETICS, INC.
TABLE 200     MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
FIGURE 42     MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2021)
15.1.4            THERMO FISHER SCIENTIFIC, INC.
TABLE 201     THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 43     THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
15.1.5            GUARDANT HEALTH, INC.
TABLE 202     GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
FIGURE 44     GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021)
15.1.6            BIO-RAD LABORATORIES, INC.
TABLE 203     BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 45     BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
15.1.7            ILLUMINA, INC.
TABLE 204     ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 46     ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
15.1.8            EXACT SCIENCES CORPORATION
TABLE 205     EXACT SCIENCES CORPORATION: BUSINESS OVERVIEW
FIGURE 47     EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2021)
15.1.9            SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
TABLE 206     SYSMEX INOSTICS: BUSINESS OVERVIEW
FIGURE 48     SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
15.1.10         BIOCEPT, INC.
TABLE 207     BIOCEPT, INC.: BUSINESS OVERVIEW
FIGURE 49     BIOCEPT, INC.: COMPANY SNAPSHOT (2021)
15.1.11         MDXHEALTH
TABLE 208     MDXHEALTH: BUSINESS OVERVIEW    244
FIGURE 50     MDXHEALTH: COMPANY SNAPSHOT (2021)
15.2          OTHER PLAYERS
15.2.1            NEOGENOMICS, INC. 246
15.2.2            EPIGENOMICS AG
15.2.3            ANGLE PLC
15.2.4            MENARINI-SILICON BIOSYSTEMS
15.2.5            VORTEX BIOSCIENCES, INC.
15.2.6            EXOSOME DIAGNOSTICS, INC.
15.2.7            MEDGENOME INC.
15.2.8            AGENA BIOSCIENCE, INC.
15.2.9            PERSONAL GENOME DIAGNOSTICS, INC.
15.2.10         FREENOME HOLDINGS, INC.
15.2.11         STRAND LIFE SCIENCES
15.2.12         LUNGLIFE AI, INC. 261
15.2.13         LUCENCE HEALTH INC.
15.2.14         ANPAC BIO-MEDICAL SCIENCE CO., LTD.
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

16   APPENDIX

16.1          DISCUSSION GUIDE
16.2          KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3          CUSTOMIZATION OPTIONS
16.4          RELATED REPORTS
16.5          AUTHOR DETAILS



△ 一番上に戻る